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Abstract
Background Multiparametric MRI (mpMRI) became recognised in investigating those with suspected prostate cancer between
2010 and 2012; in the USA, the preventative task force moratorium on PSA screening was a strong catalyst. In a few short years,
it has been adopted into daily urological and oncological practice. The pace of clinical uptake, born along by countless papers
proclaiming high accuracy in detecting clinically significant prostate cancer, has sparked much debate about the timing of
mpMRI within the traditional biopsy-driven clinical pathways. There are strongly held opposing views on using mpMRI as a
triage test regarding the need for biopsy and/or guiding the biopsy pattern.
Objective To review the evidence base and present a position paper on the role of mpMRI in the diagnosis and management of
prostate cancer.
Methods A subgroup of experts from the ESUR Prostate MRI Working Group conducted literature review and face to face and
electronic exchanges to draw up a position statement.
Results This paper considers diagnostic strategies for clinically significant prostate cancer; current national and international
guidance; the impact of pre-biopsympMRI in detection of clinically significant and clinically insignificant neoplasms; the impact
of pre-biopsy mpMRI on biopsy strategies and targeting; the notion of mpMRI within a wider risk evaluation on a patient by
patient basis; the problems that beset mpMRI including inter-observer variability.
Conclusions The paper concludes with a set of suggestions for usingmpMRI to influence who to biopsy and who not to biopsy at
diagnosis.
Key Points
• Adopt mpMRI as the first, and primary, investigation in the workup of men with suspected prostate cancer.
• PI-RADS assessment categories 1 and 2 have a high negative predictive value in excluding significant disease, and systematic
biopsy may be postponed, especially in men with low-risk of disease following additional risk stratification.
• PI-RADS assessment category lesions 4 and 5 should be targeted; PI-RADS assessment category lesion 3 may be biopsied as a
target, as part of systematic biopsies or may be observed depending on risk stratification.
Keywords Prostate cancer .Magnetic resonance imaging . Biopsy . Risk assessment . Observer variation
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Abbreviations
ADC Apparent diffusion coefficient
AUC Area under the ROC curve
CI Confidence interval
cisPCa Clinically insignificant prostate cancer
csPCa Clinically significant prostate cancer
DCE Dynamic contrast-enhanced
DRE Digital rectal examination
DWI Diffusion-weighted imaging
EAU European Association of Urology
EPE Extraprostatic extension
ERSPC European Randomised Study of Screening
for PCa
ESO European Society of Oncology
ESUR European Society of Urogenital Radiology
GG Grade grouping
GS Gleason score
IQR Interquartile range
mpMRI Multiparametric magnetic resonance imaging
MRSI Magnetic resonance spectroscopic imaging
NPV Negative predictive value
PI-RADS Prostate Imaging Reporting and Data System
PI-RADS v1 Prostate Imaging Reporting and Data
System version 1
PI-RADS v2 Prostate Imaging Reporting and Data
System version 2
PPV Positive predictive value
PSA Prostate-specific antigen
PSAd Prostate-specific antigen density
SBx Systematic biopsies
T2W T2 weighted
TBx MRI-targeted biopsies
TBx Targeted biopsy
TRUS Transrectal ultrasound
TTP Bx Template transperineal biopsy
Trial PRIAS
Trial PROTECT
Trial PRECISION
Trial PROMIS
Introduction
In 2012, the European Society of Urogenital Radiology
(ESUR) prostate committee promoted the use of
multiparametric MRI (mpMRI) in the routine management
of men with suspected or confirmed prostate cancer [1].
That proposal has gained widespread acceptance. The debate
has now moved to when mpMRI should be used.
Expressions of interest were sought from the 58 members
of the ESUR Prostate MRI Working Group at the European
Congress of Radiology (ECR) in March 2017 in contributing
to a position statement on the use of mpMRI in prostate cancer
diagnosis. Each of the 7 initial positive respondents was invit-
ed to contribute but based on the relative contributions, the
final author list was revised to 5 ensuring due representation of
the group’s European composition; a sixth contributor joined
at ECR, March 2018. The final contributors were from the
UK, France, The Netherlands, Denmark, Italy, and Belgium.
The approach was to review published evidence, supple-
mented by knowledge of completed cohort studies in the pro-
cess of being published (having been accepted for publication).
In this way, there was very little intra-author disagreement. On
the specific topic of biopsy planning—the pros and cons of
systematic versus targeted-driven approach—there was some
variation in how strongly the argument for targeted biopsy over
systematic biopsy could be worded. As the paper neared com-
pletion, the results from on-going studies became known to the
author group, such that a consensus position was reached.
Evaluating clinically significant prostate
cancer
Evaluating clinically significant prostate cancer
in the pre-MRI era
Urologists and oncologists gauge prostate cancer aggressive-
ness by combining DRE findings, serum PSA levels and data
derived from systematic biopsy findings.
Men with suspected prostate cancer are categorised into risk
groups (see EAU risk classification in EAU guidelines on pros-
tate cancer [2]). This classification is based on the grouping of
patients with a similar risk of biochemical recurrence after rad-
ical treatment [3]. Tables and nomograms have been developed
to predict the likelihood of extraprostatic spread, seminal vesi-
cle invasion and lymph node involvement, and some even state
recurrence-free survival rates at 3 and 5 years [4–8].
There is, however, still no consensus of what constitutes a
clinically significant prostate cancer (csPCa) [9]. Current argu-
ment centres on Gleason category 7 pattern 3 or 4 dominance,
ISUP grades 2 and 3, respectively. While the 2014 grading sys-
tem differentiates Gleason 7 by dominant pattern, all Gleason 7 is
classed intermediate risk, albeit with the qualification that emerg-
ing clinical data support the distinction between favourable
(ISUP grade 2) and unfavourable-risk (ISUP grade 3) patient
categories within the intermediate-risk group [2, 10, 11].
Evaluating csPCa in the post-MRI era
mpMRI can detect and localise cancers with a Gleason score
≥ 7 more easily than lower-grade cancers [12–15], relying on
the lower signal intensity of higher-grade cancers on T2-
weighted imaging (T2w), more impeded diffusion on
diffusion-weighted imaging (DWI), early enhancement on dy-
namic contrast sequences (DCE), and (previously) higher
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choline over citrate ratios on spectroscopic imaging [16–18].
mpMRI evaluates lesion volume with reasonable accuracy, at
least for aggressive tumours [19]. In one study, correlations
between lesion volume estimated on T2-weighted images,
ADC maps, and DCE-MR images with pathology were 0.91
and 0.93, respectively [20].
In 2012, the ESUR proposed a standardised reporting tool
called ‘PI-RADS’ (Prostate Imaging Reporting and Data
System) [1] in an attempt to align mpMRI findings with the
risk of having csPCa. In 2015, an updated version (PI-RADS
v2) was published in collaboration with the American College
of Radiology and the AdMeTech Foundation [21, 22] (Table 1).
PI-RADS 2 has been validated in a meta-analysis of 21 studies
including over 3857 patients. This demonstrated a pooled sen-
sitivity of 89% and a pooled specificity of 73% [23].
The EAU/ESTRO/ESUR/SIOG recommends usingmpMRI
before repeat biopsy, combining a TRUS-directed diagnostic
approach with the addition of the mpMRI and subsequently
targeted biopsies [2, 24]. Neither the European (EAU/
ESTRO/SIOG/ESUR) nor the American (NCCN) guidelines
endorse wholeheartedly mpMRI in biopsy-naïve men [2, 24].
The NICE guideline CG175 [25] has been updated and is
due for publication in April 2019 [https://www.nice.org.uk/
guidance/indevelopment/gid-ng10057]; it recommends pre-
biopsy mpMRI, putting mpMRI as the primary method to
investigate those with suspected prostate cancer based on
PSA and/or DRE findings. Revised in November 2018, the
French guidelines now also recommend pre-biopsy mpMRI
for all, including biopsy-naive [26]. Appendix 1, which in-
cludes in addition to references cited in the main text citations
to PROTECT trial [27], Belgian National Guidance [28] and
recently updated French National Guidance [29].
Eligibility criteria to have an mpMRI (in place of biopsy)
should be based on the EAU and/or National current recom-
mendations for biopsy referrals. Following suitable clinical
evaluation for acute or chronic reasons not to be investigated,
the reasons to offer mpMRI would mirror those currently used
to offer biopsy.
Pre-biopsy mpMRI advantages
The problem with any approach dominated by TRUS-guided
systematic biopsy (SBx) is that it is organ rather than lesion
based, introducing two major limitations: overdiagnosis of
clinically insignificant prostate cancers (cisPCa) and under-
diagnosis of csPCa.
The case for excluding men from biopsy based
on mpMRI
Avoiding or deferring biopsy (possibly indefinitely) if mpMRI
suggests low likelihood of csPCa would reduce the burden to
men and to their health systems of initial diagnostic workup
and low-grade prostate cancer follow-up. Such an approach
may also improve the cost efficiency of the diagnostic workup
[30]. Accepting that the results are subject to assumptions
around test costs, sensitivity of mpMRI-influenced biopsies,
and long-term outcomes of men with PCa, recent analysis of a
UK population concluded mpMRI first followed by up to 2
rounds of biopsy is more cost effective than current practice
[31]. This strategy requires a high negative predictive value
(NPV) of mpMRI in excluding csPCa.
A recent systematic review (9613 men) in conjunction with
the EAU-ESTRO-ESUR Prostate Cancer Guidelines panel
revealed a median mpMRI NPV of 82% (interquartile range
(IQR), 69–92%) for overall cancer exclusion and of 88%
(IQR, 86–92%) for csPCa exclusion [32]. The critical issue
highlighted in this review is that the reported range of the NPV
for mpMRI is extreme and varies according to definitions and
risk categorisation used.
A key variable of the NPV is the prevalence of cancer within
the population being monitored: when the prevalence doubles
from 30 to 60%, the NPVof mpMRI (scores 1–2 taken as ‘neg-
ative’) falls from 88 to 67% (for any cancer grade) (Table 2) [32].
NPV therefore is bound to be variable as it depends on whether
mpMRI is being used in a low-risk screening setting or in a
Table 1 Comparison of Prostate Imaging and Reporting and Data System versions 1 and 2 (adapted from Barentsz et al [22])
PI-RADS version 1 PI-RADS version 2
A sum score of 3–15 (20 with MRSI) for T2W+DWI +DCE
(+ MRSI) is suggested
1–5 point dominant score
For peripheral zone, DWI is dominant
For transition zone, T2W is dominant
Equal role for DCE (5-point scale) Secondary role for DCE (positive or negative)
For DWI: ADC images are mandatory For DWI: ADC and high b value images (b value > 1400) are mandatory
27-sector map 39-sector map
MRSI can be included MRSI is not included
Size is not used for T2W+DWI Size (> 15 mm) is used for T2W+DWI to separate PI-RADS scores 4 and 5
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selected high-risk cohort. Furthermore, the prevalence will alter
according to the definition of csPCa (Table 3).
Three pivotal multicentre trials on the use of mpMRI in
biopsy-naïve men inform this review: PROMIS,
PRECISION [33, 34], and the 4M study by van der Leest [35].
The PROMIS trial assessedmpMRI, 12-core SBx and tem-
plate transperineal biopsy (TTP Bx) in 576 prospectively in-
cluded biopsy-naïve men [33]. Forty percent of patients had
csPCa (defined as Gleason score ≥ 4 + 3 or cancer core length
≥ 6 mm) at TTP (Table 3). Using TTP Bx as a reference test,
the NPV for detecting csPCawas 0.89 (95%CI, 0.83–0.94) for
mpMRI compared with 0.74 (0.69–0.78) for TRUS SBx
(csPCa prevalence,: 40% (95%CI, 36–44%)). mpMRI failed
to report 7% (17/230) Gleason 3 + 4 cancers with core lengths
between 6 and 12 mm, but no Gleason 4 + 3 or worse cancers.
When accepting missing this 7%, mpMRI (used as a triage
test) could have avoided 27% of primary biopsies, while de-
tecting 18% more csPCa and ‘missing’ 5% of cisPCa [33].
The definition of csPCa propagated by the STARTconsortium
is GS ≥ 3 + 4 [36]. The usage of this definition in the PROMIS
study showed an increase in the prevalence of csPCa to 53%
(49–58%); the NPV dropped to 76% (69–82%). mpMRI
failed to report 12% Gleason 3 + 4 prostate cancers, but still
could have avoided 27% of primary biopsies.
Similar results were reported in the more recent multicentre,
randomised, noninferiority PRECISION trial, in which 500 bi-
opsy-naïve men were randomised to undergo either mpMRI
with or without targeted biopsy, or standard transrectal
ultrasonography-guided biopsy [34]. Using mpMRI as a triage
test could have avoided 28% of primary biopsies, while detect-
ing 12% more csPCa (defined as Gleason score ≥ 3 + 4) than
SBx and ‘missing’ 13% of cisPCa. These results were obtained
in 25 centres (academic and non-academic) with mixed experi-
ence in both mpMRI and MR-targeted biopsy, and without
restrictions on the use of a 1.5-T or a 3.0-T system, endorectal
coil, or biopsy technique (visual registration, software-assisted
registration or in-bore).
The 4M study included 626 biopsy-naïve patients; all pa-
tients underwent systematic biopsy, and those with a positive
mpMRI (PI-RADS 3–5, 51%) underwent additional in-bore
MRI-TBx. SBx performed in PI-RADS 1–2 cases detected
csPCa in only 3% of the patients while detecting cisPCa in
20%, with an 89% reduction in total biopsy cores [35].
In a clinical follow-up study (median follow-up of
41 months) of a mixed population of biopsy-naïve, repeat
biopsies, and active surveillance (n = 300), who had under-
gone a negative in-bore MR-guided biopsy for PI-RADS 3–
5 lesions, only 1.7% (5/300) had csPCa subsequently diag-
nosed by any kind of follow-up histology in 82 men (any
biopsy or radical prostatectomy), and in 218 without any his-
tology confirmation [37]. In another cohort of 1255 patients
with negative mpMRI, the csPCa-free survival rates at
48 months were 95% in originally biopsy-naïve patients and
96% in patients with a prior negative biopsy [38].
Improving detection of csPCa
Pre-biopsy mpMRI in men with suspected prostate cancer is
justified further if it improves the detection of csPCa through
targeted biopsies of any suspicious lesion suggested by mpMRI.
Radiologic-pathologic correlations with whole-mounts
have shown that mpMRI is highly sensitive for locating ag-
gressive cancers, with 80–86% of Gleason 7 and 93–100% of
Gleason ≥ 8 detected [12]. Correlation studies of mpMRI with
TBx or radical prostatectomy specimens performed after the
introduction of PI-RADS showed that the location of the in-
dex lesion was correctly assessed by mpMRI in 95% of pa-
tients [39] and that mpMRI missed 10% csPCa on a per-lesion
basis [40]. mpMRI results, whether expressed as subjective
(Likert) scoring [41–43], PI-RADS v1 [44, 45], or PI-RADS
v2 scoring [46], were found significant predictors of the pres-
ence of csPCa at biopsy.
A recent systematic review of mostly retrospective studies
showed that TBx performed under MR/TRUS fusion detected
more csPCa than SBx, with a median detection rate of 33.3%
(range, 13.2–50%) versus 23.6% (range, 4.8–52%), respectively.
The absolute difference in the detection rates between the two
approaches was a median of 6.8% (range, 0.9–41.4%) and
Table 2 Negative predictive estimates for pre-biopsy mpMRI as a func-
tion of prostate cancer prevalence (adapted from Molovan et al [32])
PCa prevalence NPV
0.30 0.88 (0.77–0.99)
0.40 0.82 (0.70–0.94)
0.50 0.76 (0.64–0.88)
0.60 0.67 (0.56–0.79)
0.70 0.57 (0.47–0.67)
Table 3 Diagnostic accuracy results from mpMRI for different definitions of clinically significant prostate cancer (adapted from PROMIS study [33])
Definition of csPCa Prevalence (%) Sensitivity Specificity PPV NPV
Gleason score ≥ 3 + 4 or cancer core length ≥ 4 mm, 57 (53–62) 87 (83–90) 47 (40–53) 69 (64–73) 72 (65–79)
Gleason score ≥ 3 + 4 53 (49–58) 88 (84–91) 45 (39–51) 65 (60–69) 76 (69–82)
Gleason score ≥ 4 + 3 or cancer core length ≥ 6 mm 40 (36–44) 93 (88–96) 41 (36–46) 51 (46–56) 89 (83–94)
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always in favour of TBx. The median number of biopsy cores to
detect one man with csPCa was 37.1 (IQR, 32.6–82.8) and 9.2
(IQR, 4–37.7) for SBx and TBx, respectively [47]. Another sys-
tematic review (focussing on MRI positive men only), including
studies that used MR/TRUS fusion, cognitive guidance, or in-
bore guidance for TBx, also found that TBx has a higher rate of
detection of csPCa than SBx with a sensitivity of 0.91 (95%CI,
0.87–0.94) and 0.76 (95%CI, 0.64–0.84), respectively, in a
mixed population of biopsy-naïve men and men with previous
negative biopsies [48]. The sensitivity (detection) ratio was 1.10
(95%CI, 1.00–1.22) and significantly in favour of TBx for biop-
sy-naïve men only, and 1.54 (95%CI, 1.05, 2.26) in men with
previous negative biopsies. In a head-to-head comparison in 223
men with elevated PSA and/or abnormal DRE, mpMRI-
influenced biopsy outperformed systematic 12-core TRUS biop-
sy in detecting csPCa on a patient basis (42% vs 35%) and on a
lesion basis (74% vs 61%) with a ‘miss rate for significant le-
sions’ of ~ 18% in the MRI biopsy group versus ~ 26% rate in
the TRUS biopsy group [49].
Targeted versus systematic biopsy versus combined
approach for clinically significant prostate cancer
detection
mpMRI-targeted biopsies detect about 90% of all csPCa [12,
33, 48]. This, however, also means that about 10% of csPCa are
missed if only a targeted approach is adopted. Indeed, histolog-
ical correlation highlights that Gleason ≥ 7 cancers can be in-
visible on mpMRI [12]. It therefore may seem prudent, on first
thoughts, to supplement targeted biopsies with systematic biop-
sies to ‘capture’ any csPCa that is missed by mpMRI (usually
low grade 4 and organ-confined [50], located in the dorsolateral
or apical segments of the peripheral zone [49]).
The combination of SBx and MRI-targeted biopsies (TBx)
comes at a cost: over-detection of cisPCa [51, 52]. In a system-
atic review of 16 studies comparing TBx and SBx in mixed
populations of biopsy-naïve men and men with previous nega-
tive biopsies, this overdiagnosis was almost halved by omitting
SBx [48]. In the PRECISION trial, 13% (95% CI, − 19 to −
7%; p < 0.001) fewer men were diagnosed with cisPCa in the
MRI-targeted biopsy group (in total 9%) than in the standard
biopsy group (in total 22%); again, this diagnosis was more
than halved by omitting SBx. Likewise, in a prospective non-
randomised trial of 1003 men who underwent both TBx and
SBx, adding SBx to TBx identified an additional 103 (22%)
prostate cancers, 83% of which were low-grade [53].
Excluding SBx in the MRI-negative men in the 4M would
have avoided biopsies in 49% in this study population at a
small expense of missing csPCa [35].
The MRI-FIRST multicentre study [54] recruited biopsy-
naïve men (n = 251) under 75 years with a PSA ≤ 20 ng/ml.
All patients had 12-core SBx plus 2 optional cores to
hypoechoic lesions by one operator blinded tompMRI results,
and TBx (up to 2 targeted lesions, 3 cores per lesion) by
another operator. SBx and TBx detection rates for ISUP grade
≥ 2 tumours were 29.9% and 32.3%, respectively (p = 0.38;
detection ratio 1.08). ISUP grade ≥ 2 cancers would have been
missed in 7.6% (95%CI, 4.6–11.6%) of patients if TBx had
not been taken, and in 5.2% (95%CI, 2.8–8.7%) of patients if
SBx had not been performed. TBx detected significantly more
ISUP grade ≥ 3 tumours than SBx (19.9% vs 15.1%, p =
0.0095; detection ratio, 1.32). ISUP grade ≥ 3 cancers would
have been missed in 6.0% (95%CI, 3.4–9.7%) of patients if
TBx had not been taken, but in only 1.2% (95%CI, 0.2–3.5%)
of patients if SBx had not been performed. These data indicate
that predominantly ISUP grade 2 prostate cancers were detect-
ed by the inclusion of SBx.
Technology that allows mapping exactly the biopsy needle
path has suggested that the median number of systematic cores
sampling the same region selected for target is 2. If these
‘isometric’ systematic cores are disregarded, systematic biop-
sy has a modest benefit only: 3% cancer detection instead of
benign diagnosis and ~ 1% from cisPCa to csPCa [55].
There are few data comparing TBx to TTP Bx. TTP Bx
should be considered in patients at high risk with negative
mpMRI and in some patients at low-risk with persistently
elevated PSA and a negative MRI.
Biopsy strategy in the ‘mpMRI first’ era
It is impossible to brush aside that the range of published
mpMRI NPV figures is broad and that csPCa prevalence
(i.e. pre-MRI probability of csPCa) has a major impact on
NPV [9, 32]. Therefore, there is a need to refine the biopsy
planning process by incorporating the mpMRI findings within
a larger nomogram containing clinical data to determine an
individual’s likelihood of having csPCa.
In a recent multivariate logistic regression analysis to pre-
dict likelihood of csPCa for biopsy-naive and previously
biopsied men, the PI-RADS classification contributed signif-
icantly to a newly developed risk model (p < 0.001) in com-
bination with the ERSPC-RCs (www.prostatecancer-
riskcalculator.com) based on the European Randomised
Study of Screening for PCa (ERSPC) [56, 57]. For biopsy-
naive men, the risk model reached a higher AUC (0.83), com-
pared with ERSPC-RC3 (0.81), refitted RC3 (0.80), and PI-
RADSv1.0 (0.76). The risk model AUC was comparable with
that of ERSPC-RC3 + PI-RADSv1.0 (0.84). Likelihood ratio
test results similarly showed that the risk-models may perform
significantly better compared with (refitted) ERSPCs and PI-
RADS alone. Others have confirmed these results [58].
PI-RADS 3 lesions and risk stratification and biopsy
PI-RADS assessment category 3 is assigned when the proba-
bility of prostate cancer is uncertain. The percentage of
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patients assigned a PI-RADS assessment category of 3 is ex-
tremely variable in the different published cohorts [59]. As
expected, the biopsy positivity rate is also highly variable in
these lesions; the cumulative total of high-grade PCa (GS ≥
3 + 4) in the PI-RADS category 3 has been reported 21%
(range 4–27%) in biopsy-naïve men and 16% (range 10–
19%) men with previous negative biopsies [59]. Another pa-
per lists overall cancer detection 16–67% and proportion of
Gleason ≥ 7 cancers 0–43% [46]. Based on these data, the
authors concluded that the prevalence of PI-RADS 3 index
lesions in the diagnostic workup is not negligible, varying
between one in five (22%) and one in three (32%) men, de-
pending on patient cohort of the first biopsies or previous
negative biopsies. The actual prevalence of csPCa after TBx
in PI-RADS category 3 lesions varies between patient groups
from one in five (21%) and one in six (16%), depending on
previous biopsy status. Although this prevalence is lower in
comparison to PI-RADS category 4 and PI-RADS category 5
lesions, still a considerable proportion of men harbour signif-
icant disease.
Biopsy strategy and patient risk
Biopsy decisions should first be based on mpMRI findings,
favouring avoiding biopsy in ‘negative’ (any/all lesions PI-
RADS 2 or less) studies and targeting PI-RADS 4 or 5 lesions.
For some ‘negative’ studies and most PI-RADS 3 lesions, a
second assessment incorporating clinical (age, DRE, family
history for example) and biochemical (PSA density and ve-
locity) parameters should be applied to see if systematic biop-
sy alone or in addition to targets to the low-grade PI-RADS
lesions are indicated.
The use of PSA density may improve the patient selection
for biopsy [32, 35, 56, 57, 60–65]. Two studies using either
the PI-RADSV1 scoring [66] or a mix of PI-RADS v1 and v2
systems [37] suggested that PSA density could discriminate
among PI-RADS 3 patients, those who need to undergo pros-
tate biopsy from those who can be followed up. In a
multicentre study of biopsy-naïve men, PI-RADS category 3
lesions were further categorised into PSA density of < 0.10,
0.10–0.20, and > 0.20: the detection of GS ≥ 3 + 4 PCa was
18%, 31%, 46%, respectively [67].
In patients stratified into a priori low-to-intermediate risk
(Table 1), the mpMRI NPV is probably sufficiently high to
avoid SBx in case of negativempMRI [34]. Systematic biopsy
results would be expected to be less influential on patient
management in the setting of a positive mpMRI with a suspi-
cious lesion than in a negative mpMRI. In high-risk patients,
however, patients with negative mpMRI will probably still
need SBx [34]; even in expert centres, mpMRI may ‘miss’
10–12% csPCa. The recommended shift towards an MRI-
directed and risk-stratified approach to seeking csPCa is cap-
tured in the flowchart (Fig. 1). A shift in emphasis away from
SBx with additional MRI-TBx to MRI-TBx for high-
probability mpMRI examinations is recommended, accepting
the modest price of missing csPCa [33, 68–75].
Biopsy Naïve Men
PCa suspicion
mpMRI
PI-RADS 
1-2
Risk Straficaon
(nomograms)
SBx +/- TBx (P3)
Clinical follow-up
PI-RADS
3
PI-RADS
4-5
TBx 
+/- SBx (focal therapy)
Therapy 
(including acve surveillance
Risk Straficaon
(nomograms)
Red line
High risk or posive for 
Gleason 7 
Green line
Low risk or Biopsy negave 
(Gleason 6 or lower)
Dashed lines 
indicate possible added risk 
evaluaon step
Fig. 1 Proposed flowchart for investigating men suspected having
prostate cancer, beginning with mpMRI. Using mpMRI as the primary
investigation in prostate cancer diagnostic workup following clinical
suspicion, men will be stratified into PI-RADS assessment categories
1–2, 3, and 4–5. Capitalising on the high negative predictive value of
mpMRI, assessment category 1–2 may indicate clinical follow-up
avoiding systematic biopsy, or indicate further risk stratification with
developing risk calculators (nomograms). Assessment category 3 may
indicate MR-targeted biopsy (TBx) combined with systematic biopsy
(SBx) to gain maximal diagnostic yield. Alternatively, risk stratification
may sub-differentiate these men into high-risk and low-risk; the low-risk
group may defer systematic biopsy. Assessment category 4–5 may
indicate MR-targeted biopsy. Systematic biopsy could be performed in
direct combination or secondary, depending on biopsy workflow. In as-
sessment category 5, the added value of systematic biopsy would be
limited. When prostate cancer has not been identified, additional risk
stratification could be performed to indicate or avoid additional system-
atic and targeted biopsy. Green arrows, low-risk; red arrows, intermedi-
ate-/high-risk. Dotted lines indicate research in progress. PCa, prostate
cancer; MRI, magnetic resonance; PI-RADS, prostate imaging reporting
and data system = suspicionMRI score (1–5); TBx,MRI-targeted biopsy;
SBx, transrectal/transperineal ultrasound-guided systematic biopsy; AS,
active surveillance
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Inter-reader variability
There are three difficulties with the widespread introduc-
tion of pre-biopsy mpMRI: the variable NPV of mpMRI,
the variable accuracy of using mpMRI with TRUS to tar-
get suspicious lesions regardless of their location within
the prostate gland, and inter-reader variability. The results
from studies addressing the variability between 2013 and
2017 are summarised in Table 4.
The conclusions from the studies are succinctly captured
by Hansen et al [88]: (1) mpMRI exams are more often called
negative in subspecialist reads (41% vs 20%); (2) second read-
ings of prostate mpMRI by subspecialist uroradiologists sig-
nificantly improve NPVand PPV; (3) reporter experience may
reduce overcalling and avoid over targeting of lesions; and (4)
greater education and training of radiologists in prostate
mpMRI interpretation are advised. Many European countries
are, in collaboration with ESUR and EAU, working to address
this training need.
Conclusion
Current national guidelines in Europe highlight the worth
of mpMRI in the management of men with suspected
PCa. The case for using mpMRI to help in selecting
which men with suspected PCa should have a biopsy—
and which need not—and to then select the regions of the
prostate to biopsy (and which regions can be ignored) is
compelling. The evidence base, including level 1 studies,
is overpowering as are the arguments for patient benefit,
avoiding either biopsy or overdiagnosis of clinically in-
significant cancer.
Patients contemplating a biopsy are becoming aware
that imaging by means of mpMRI may permit avoidance
of biopsy in some cases and targeting in others. These
patients will be understandably anxious to avoid the risks
of biopsy, or at least minimise the risks by having fewer
biopsy samples. Going away from ‘default’ SBx to pre-
meditated TBx judiciously and selectively complimented
by SBx using a two-step risk evaluation offers the best
compromise to reduce biopsy rates and reduce overdiag-
nosis of cisPCa while minimising the chances of missing
csPCa. The evidence to expect to avoid SBx altogether
even in the era of pre-biopsy mpMRI is weak [54].
Our summary suggestions are presented in Table 5.
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